Following these transactions, Schneider's direct ownership in Ionis Pharmaceuticals (NASDAQ:IONS) stands at 58,508 shares.

OpenAI is making a foray into scientific discovery with an AI built to help manufacture stem cells. When you think of AI’s contributions to science, you probably think of AlphaFold, the Google ...

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage company that develops, discovers, manufactures, and ...

Everything touching artificial intelligence (AI) is hot right now, so it's no surprise that the biotech Recursion ...

MoneywebNOW took a look at residential property challenges, ETF distributions, Reit prospects, and how AI could boost biotech ...

With new legislation and noteworthy policies on sci-tech and innovation expected this year, businesses are hoping the right ...

Selective stock-picking and conviction drove HB Biotech’s strong 2024 performance. Read our insights on navigating today’s ...

With the use of deep learning and advanced algorithms, generative AI can promote acceleration in the design and development ...

Artificial intelligence could be the future of humanity and we mustn’t let it slip out of human control. GenAI tools are just ...

The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...